Compare DFH & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFH | VCEL |
|---|---|---|
| Founded | 2008 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2020 | 1996 |
| Metric | DFH | VCEL |
|---|---|---|
| Price | $15.57 | $32.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $26.00 | ★ $58.50 |
| AVG Volume (30 Days) | ★ 474.9K | 412.7K |
| Earning Date | 05-28-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 2.14 | 0.32 |
| Revenue | ★ $4,322,848,000.00 | $276,259,000.00 |
| Revenue This Year | $1.48 | $19.09 |
| Revenue Next Year | $6.88 | $17.96 |
| P/E Ratio | ★ $7.38 | $104.28 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $14.88 | $29.24 |
| 52 Week High | $31.10 | $48.75 |
| Indicator | DFH | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 23.69 | 34.92 |
| Support Level | N/A | $31.34 |
| Resistance Level | $20.26 | $38.48 |
| Average True Range (ATR) | 0.84 | 1.42 |
| MACD | -0.41 | -0.36 |
| Stochastic Oscillator | 9.67 | 4.86 |
Dream Finders Homes Inc designs, builds and sells homes in markets throughout the United States. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the maximum of its revenue from the Midwest segment.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.